To further explore the potential of Ki67+ Treg cells as a general predictor of ICI response and benefit in other types of cancer including NSCLC and melanoma, we calculated a Ki67+ Treg signature score using bulk RNA sequencing data and classified patients into low and high groups according to the median score. The gene discussed is MKI67; the disease is melanoma.